|
1
|
Grier HE: The Ewing family of tumors.
Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin
North Am. 44:991–1004. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Esiashvili N, Goodman M and Marcus RB Jr:
Changes in incidence and survival of Ewing sarcoma patients over
the past 3 decades: Surveillance epidemiology and end results data.
J Pediatr Hematol Oncol. 30:425–430. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosen G, Wollner N, Tan C, Wu SJ, Hajdu
SI, Cham W, D'Angio GJ and Murphy ML: Proceedings: Disease-free
survival in children with Ewing's sarcoma treated with radiation
therapy and adjuvant four-drug sequential chemotherapy. Cancer.
33:384–393. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng VY, Jones R, Bompadre V, Louie P, Punt
S and Conrad EU III: The effect of surgery with radiation on pelvic
Ewing sarcoma survival. J Surg Oncol. 112:861–865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brohl AS, Solomon DA, Chang W, Wang J,
Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, et al: The
genomic landscape of the Ewing Sarcoma family of tumors reveals
recurrent STAG2 mutation. PLoS Genet. 10:e10044752014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
May WA, Arvand A, Thompson AD, Braun BS,
Wright M and Denny CT: EWS/FLI1-induced manic fringe renders NIH
3T3 cells tumorigenic. Nat Genet. 17:495–497. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Delattre O, Zucman J, Plougastel B,
Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau
G, et al: Gene fusion with an ETS DNA-binding domain caused by
chromosome translocation in human tumours. Nature. 359:162–165.
1992. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka K, Iwakuma T, Harimaya K, Sato H
and Iwamoto Y: EWS-Fli1 antisense oligodeoxynucleotide inhibits
proliferation of human Ewing's sarcoma and primitive
neuroectodermal tumor cells. J Clin Invest. 99:239–247. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Alava E, Kawai A, Healey JH, Fligman I,
Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR,
et al: EWS-FLI1 fusion transcript structure is an independent
determinant of prognosis in Ewing's sarcoma. J Clin Oncol.
16:1248–1255. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Riggi N, Knoechel B, Gillespie SM,
Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O,
Cook EB, et al: EWS-FLI1 utilizes divergent chromatin remodeling
mechanisms to directly activate or repress enhancer elements in
Ewing sarcoma. Cancer Cell. 26:668–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang SW, Bilke S, Cao L, Murai J, Sousa
FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, et al:
SLFN11 Is a transcriptional target of EWS-FLI1 and a determinant of
drug response in Ewing sarcoma. Clin Cancer Res. 21:4184–4193.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He T, Surdez D, Rantala JK, Haapa-Paananen
S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, et al:
High-throughput RNAi screen in Ewing sarcoma cells identifies
leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a
regulator of EWS-FLI1 driven cell viability. Gene. 596:137–146.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niedan S, Kauer M, Aryee DN, Kofler R,
Schwentner R, Meier A, Pötschger U, Kontny U and Kovar H:
Suppression of FOXO1 is responsible for a growth regulatory
repressive transcriptional sub-signature of EWS-FLI1 in Ewing
sarcoma. Oncogene. 33:3927–3938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tancredi R, Zambelli A, DaPrada GA,
Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ and D'Incalci
M: Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
Cancer Chemother Pharmacol. 75:1317–1320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gupta AK, Fleckman P and Baran R:
Ciclopirox nail lacquer topical solution 8% in the treatment of
toenail onychomycosis. J Am Acad Dermatol. 43 4 Suppl:S70–S80.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bohn M and Kraemer KT: Dermatopharmacology
of ciclopirox nail lacquer topical solution 8% in the treatment of
onychomycosis. J Am Acad Dermatol. 43 4 Suppl:S57–S69. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clement PM, Hanauske-Abel HM, Wolff EC,
Kleinman HK and Park MH: The antifungal drug ciclopirox inhibits
deoxyhypusine and proline hydroxylation, endothelial cell growth
and angiogenesis in vitro. Int J Cancer. 100:491–498. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu
B, Han X, Pang J, Rivera CA and Huang S: The antitumor activity of
the fungicide ciclopirox. Int J Cancer. 127:2467–2477. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sen S, Hassane DC, Corbett C, Becker MW,
Jordan CT and Guzman ML: Novel mTOR inhibitory activity of
ciclopirox enhances parthenolide antileukemia activity. Exp
Hematol. 41:799–807.e4. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bilke S, Schwentner R, Yang F, Kauer M,
Jug G, Walker RL, Davis S, Zhu YJ, Pineda M, Meltzer PS and Kovar
H: Oncogenic ETS fusions deregulate E2F3 target genes in Ewing
sarcoma and prostate cancer. Genome Res. 23:1797–1809. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goss KL and Gordon DJ: Gene expression
signature based screening identifies ribonucleotide reductase as a
candidate therapeutic target in Ewing sarcoma. Oncotarget.
7:63003–63019. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang YH, Dudoit S, Luu P, Lin DM, Peng V,
Ngai J and Speed TP: Normalization for cDNA microarray data: A
robust composite method addressing single and multiple slide
systematic variation. Nucleic Acids Res. 30:e152002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Vasaikar S, Shi Z, Greer M and
Zhang B: WebGestalt 2017: A more comprehensive, powerful, flexible
and interactive gene set enrichment analysis toolkit. Nucleic Acids
Res. May 3–2017. View Article : Google Scholar
|
|
24
|
Supek F, Bošnjak M, Škunca N and Šmuc T:
REVIGO summarizes and visualizes long lists of gene ontology terms.
PLoS One. 6:e218002011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Langmead B and Salzberg SL: Fast
gapped-read alignment with Bowtie 2. Nat Methods. 9:357–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng J, Liu T, Qin B, Zhang Y and Liu XS:
Identifying ChIP-seq enrichment using MACS. Nat Protoc.
7:1728–1740. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu G, Wang LG and He QY: ChIPseeker: An
R/Bioconductor package for ChIP peak annotation, comparison and
visualization. Bioinformatics. 31:2382–2383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thorvaldsdóttir H, Robinson JT and Mesirov
JP: Integrative genomics viewer (IGV): High-performance genomics
data visualization and exploration. Brief Bioinform. 14:178–192.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dittmar W and Lohaus G: HOE 296, a new
antimycotic compound with a broad antimicrobial spectrum.
Laboratory results. Arzneimittelforschung. 23:670–674.
1973.PubMed/NCBI
|
|
32
|
Ceschin-Roques CG, Hänel H, Pruja-Bougaret
SM, Luc J, Vandermander J and Michel G: Ciclopirox nail lacquer 8%:
In vivo penetration into and through nails and in vitro effect on
pig skin. Skin Pharmacol. 4:89–94. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gupta AK: Ciclopirox: An overview. Int J
Dermatol. 40:305–310. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Minden MD, Hogge DE, Weir SJ, Kasper J,
Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, et
al: Oral ciclopirox olamine displays biological activity in a phase
I study in patients with advanced hematologic malignancies. Am J
Hematol. 89:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou HY, Shen T, Luo Y, Liu L, Chen W, Xu
B, Han X, Pang J, Rivera CA and Huang S: The antitumor activity of
the fungicide ciclopirox. Int J Cancer. 10:2467–2477. 2010.
View Article : Google Scholar
|
|
36
|
Eberhard Y, McDermott SP, Wang X, Gronda
M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, et
al: Chelation of intracellular iron with the antifungal agent
ciclopirox olamine induces cell death in leukemia and myeloma
cells. Blood. 114:3064–3073. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grohar PJ, Segars LE, Yeung C, Pommier Y,
D'Incalci M, Mendoza A and Helman LJ: Dual targeting of EWS-FLI1
activity and the associated DNA damage response with trabectedin
and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin
Cancer Res. 20:1190–1203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grohar PJ, Kim S, Rangel Rivera GO, Sen N,
Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, et
al: Functional genomic screening reveals splicing of the EWS-FLI1
fusion transcript as a vulnerability in Ewing Sarcoma. Cell Rep.
14:598–610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Minas TZ, Surdez D, Javaheri T, Tanaka M,
Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, et al: Combined
experience of six independent laboratories attempting to create an
Ewing sarcoma mouse model. Oncotarget. 8:34141–34163. 2016.
|
|
40
|
Asano Y, Markiewicz M, Kubo M, Szalai G,
Watson DK and Trojanowska M: Transcription factor Fli1 regulates
collagen fibrillogenesis in mouse skin. Mol Cell Biol. 29:425–434.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsai YP and Wu KJ: Hypoxia-regulated
target genes implicated in tumor metastasis. J Biomed Sci.
19:1022012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Elzi DJ, Song M, Hakala K, Weintraub ST
and Shiio Y: Proteomic analysis of the EWS-Fli-1 interactome
reveals the role of the Lysosome in EWS-Fli-1 turnover. J Proteome
Res. 13:3783–3791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cutroneo KR, White SL, Phan SH and Ehrlich
HP: Therapies for bleomycin induced lung fibrosis through
regulation of TGF-beta1 induced collagen gene expression. J Cell
Physiol. 211:585–589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen SJ, Yuan W, Mori Y, Levenson A,
Trojanowska M and Varga J: Stimulation of type I collagen
transcription in human skin fibroblasts by TGF-beta: Involvement of
Smad 3. J Invest Dermatol. 112:49–57. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Verrecchia F, Chu ML and Mauviel A:
Identification of novel TGF-β/Smad gene targets in dermal
fibroblasts using a combined cDNA microarray/promoter
transactivation approach. J Biol Chem. 276:17058–17062. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hahm KB: Repression of the gene encoding
the TGF-beta type II receptor is a major target of the EWS-FLI1
oncoprotein. Nat Genet. 23:4811999. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Semenza GL: Hypoxia-inducible factor 1:
Oxygen homeostasis and disease pathophysiology. Trends Mol Med.
7:345–350. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X,
Fang J and Jiang BH: Reactive oxygen species regulate epidermal
growth factor-induced vascular endothelial growth factor and
hypoxia-inducible factor-1 alpha expression through activation of
AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med.
41:1521–1533. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Simon MC and Keith B: The role of oxygen
availability in embryonic development and stem cell function. Nat
Rev Mol Cell Biol. 9:285–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Low-Marchelli JM, Ardi VC, Vizcarra EA,
van Rooijen N, Quigley JP and Yang J: Twist1 induces CCL2 and
recruits macrophages to promote angiogenesis. Cancer Res.
73:662–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gort EH, van Haaften G, Verlaan I, Groot
AJ, Plasterk RH, Shvarts A, Suijkerbuijk KP, van Laar T, van der
Wall E, Raman V, et al: The TWIST1 oncogene is a direct target of
hypoxia-inducible factor-2alpha. Oncogene. 27:1501–1510. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dehne N and Brüne B: Sensors,
transmitters, and targets in mitochondrial oxygen shortage-a
hypoxia-inducible factor relay story. Antioxidants Redox Signal.
20:339–352. 2014. View Article : Google Scholar
|
|
53
|
Zhdanov AV, Waters AH, Golubeva AV and
Papkovsky DB: Differential contribution of key metabolic substrates
and cellular oxygen in HIF signalling. Exp Cell Res. 330:13–28.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Somers GR, Zielenska M, Abdullah S,
Sherman C, Chan S and Thorner PS: Expression of MYCN in pediatric
synovial sarcoma. Modern Pathol. 20:734–741. 2007. View Article : Google Scholar
|
